A new monoclonal antibody drug has become available in the U.S., as the Food and Drug Administration () authorized Ely Lilly's bebtelovimab for use in non-hospitalized Covid patients who are at a high risk of severe complications from the virus.The move comes only weeks after the agency pulled authorization from another monoclonal antibody treatment produced by Eli Lilly - along with a drug produced by Regeneron - since they were deemed to be ineffective against the variant.This drug showed effectiveness against the strain that now makes up nearly 100 percent of active cases in the U.S., though, and will soon begin to be administered to infected patients.
Load More
Load More